1. A Drug–Drug Cocrystal of Dihydromyricetin and Pentoxifylline
- Author
-
Lei Liu, Mei Zhang, Zhang Yanjie, Yanguang Li, and Benyong Lou
- Subjects
Drug ,Flavonols ,media_common.quotation_subject ,Pharmaceutical Science ,02 engineering and technology ,Crystallography, X-Ray ,030226 pharmacology & pharmacy ,Cocrystal ,Pentoxifylline ,03 medical and health sciences ,0302 clinical medicine ,X-Ray Diffraction ,Aqueous solubility ,medicine ,Solubility ,media_common ,Chemistry ,Sorption ,021001 nanoscience & nanotechnology ,Hepg2 cells ,Crystallization ,0210 nano-technology ,Hydrate ,human activities ,medicine.drug ,Nuclear chemistry - Abstract
Drug-drug cocrystals, which can regulate physicochemical properties of individual drugs and might produce synergistic therapeutic effects, have drawn growing interest in the pharmaceutical industry. In this study, a novel drug-drug (1:1) cocrystal hydrate of slightly water-soluble dihydromyricetin (DMY) and highly water-soluble pentoxifylline (PTX), DMY-PTX•H2O (1), was prepared by a slurry method. The single-crystal X-ray diffraction results reveal that the cocrystal is formed through hydrogen-bonding interactions between hydroxyl groups of DMY and four acceptors of PTX. The dynamic vapour sorption results indicate that the cocrystal displays reduced hydrophilicity compared with DMY. It is found that cocrystal formation narrows the solubility difference between two parent drugs. The equilibrium solubility of PTX decreases greatly, while that of DMY increases slightly. As a result, DMY and PTX are synchronously and sustainedly released from the cocrystal. Further, a synergistic anti-cancer effect of the cocrystal DMY-PTX•H2O (1) on HepG2 cells in vitro at a drug concentration of 100 μM was discovered. This study brings evidence of cocrystallization as a successful approach for synchronous sustained-release of two drugs with substantially different aqueous solubility.
- Published
- 2022